Aplastic Anaemia Sample Clauses

Aplastic Anaemia. Chronic persistent bone marrow failure, confirmed by biopsy, which results in anaemia, neutropenia and thrombocytopenia requiring treatment with at least one of the following: • Blood product transfusion; • Marrow stimulating agents; • Immunosuppressive agents; or • Bone marrow transplantation. The diagnosis must be confirmed by a haematologist.
Sample 1Sample 2Sample 3See All (15)
AutoNDA by SimpleDocs
Aplastic Anaemia. A Chronic persistent bone marrow failure which results in total aplasia of the bone marrow and requires treatment with at least one of the following: a) Regular blood product transfusion b) Marrow stimulating agents c) Immunosuppressive agents d) Bone marrow transplantation The diagnosis and suggested line of treatment must be confirmed by a Haematologist using relevant laboratory investigations including Bone Marrow Biopsy. Two out of the following three values should be present: 1. Absolute Neutrophil count of 500 per cubic millimetre or less; 2. Absolute Reticulocyte count of 20,000 per cubic millimetre or less; and 3. Platelet count of 20,000 per cubic millimetre or less.
Sample 1Sample 2Sample 3See All (12)
Aplastic Anaemia. I) Chronic persistent bone marrow failure which results in anaemia, neutropenia and thrombocytopenia requiring treatment with at least one of the following: i) Blood product transfusion; ii) Marrow stimulating agents; iii) Immunosuppressive agents; or iv) Bone marrow transplantation. II) The diagnosis must be confirmed by a haematologist using relevant laboratory investigations including Bone Marrow Biopsy resulting in bone marrow cellularity of less than 25% which is evidenced by any two of the following: i) Absolute neutrophil count of 500/mm³ or less ii) Platelets count less than 20,000/mm³ or less iii) Absolute Reticulocyte count of 20,000/mm³ or less III) Temporary or reversible Aplastic Anaemia is excluded. IV) In this condition, the bone marrow fails to produce sufficient blood cells or clotting agents.
Sample 1Sample 2Sample 3
Aplastic Anaemia. Chronic Irreversible persistent bone marrow failure which results in Anaemia, Neutropenia and Thrombocytopenia requiring treatment with at least TWO of the following: I. Regular blood product transfusion; II. Marrow stimulating agents; III. Immunosuppressive agents; or IV. Bone marrow transplantation. The diagnosis and suggested line of treatment must be confirmed by a Hematologist acceptable to the Company using relevant laboratory investigations, including bone-marrow biopsy. Two out of the following three values should be present: I. Absolute neutrophil count of 500 per cubic millimeter or less; II. Absolute erythrocyte count of 20 000 per cubic millimeter or less; and III. Platelet count of 20 000 per cubic millimeter or less. Temporary or reversible aplastic anaemia is excluded.
Sample 1Sample 2
Aplastic Anaemia. Chronic persistent bone marrow failure which results in anaemia, neutropenia and thrombocytopenia requiring treatment with at least one of the following: a. Blood product transfusion; b. Marrow stimulating agents; c. Immunosuppressive agents; or d. Bone marrow transplantation. The diagnosis must be confirmed by a haematologist using relevant laboratory investigations including Bone Marrow Biopsy resulting in bone marrow cellularity of less than 25% which is evidenced by any two of the following: a. Absolute neutrophil count of 500/mm³ or less b. Platelets count less than 20,000/mm³ or less c. Absolute Reticulocyte count of 20,000/mm³ or less Temporary or reversible Aplastic Anaemia is excluded. In this condition, the bone marrow fails to produce sufficient blood cells or clotting agents.
Sample 1Sample 2
Aplastic Anaemia. Chronic persistent bone marrow failure which results in anaemia, neutropenia and thrombocytopenia requiring treatment with at least one of the following: a. Blood product transfusion; b. Marrow stimulating agents; c. Immunosuppressive agents; or d. Bone marrow transplantation. The diagnosis must be confirmed by a haematologist using relevant laboratory investigations including Bone Marrow Biopsy resulting in bone marrow cellularity of less than 25% which is evidenced by any two of the following: a. Absolute neutrophil count of 500/mm³ or less b. Platelets count less than 20,000/mm³ or less
Sample 1Sample 2
Aplastic Anaemia. Chronic persistent bone marrow failure which results in anaemia, neutropenia and thrombocytopenia requiring treatment with at least one of the following:
Sample 1
AutoNDA by SimpleDocs
Aplastic Anaemia. Chronic persistent bone marrow failure which results in anaemia, neutropenia and thrombocytopenia requiring treatment with at least one of the following: a. Blood product transfusion; b. Marrow stimulating agents; c. Immunosuppressive agents; or ManipalCigna Lifestyle Protection - Critical Care | Terms & Conditions | UIN: MCIHLIP21125V022021 | October 2021 d. Bone marrow transplantation. The diagnosis must be confirmed by a haematologist using relevant laboratory investigations including Bone Marrow Biopsy resulting in bone marrow cellularity of less than 25% which is evidenced by any two of the following - a) Absolute neutrophil count of less than 500/mm³ or less b) Platelets count less than 20,000/mm³ or less c) Reticulocyte count of less than 20,000/mm³ or less Temporary or reversible Aplastic Anaemia is excluded.
Sample 1
Aplastic Anaemia. Unequivocal diagnosis of bone marrow failure confirmed by a specialist and evidenced by the result of bone marrow biopsy. Disease must result in anaemia, neutropenia and thrombocytopenia and must require treatment with at least one of the following: a) blood product transfusion b) marrow stimulating agents c) immunosuppressive agents d) bone marrow transplantation
Sample 1

Related to Aplastic Anaemia

  • Hepatitis B Vaccine Where the Hospital identifies high risk areas where employees are exposed to Hepatitis B, the Hospital will provide, at no cost to the employees, a Hepatitis B vaccine.

  • Human Leukocyte Antigen Testing This plan covers human leukocyte antigen testing for A, B, and DR antigens once per member per lifetime to establish a member’s bone marrow transplantation donor suitability in accordance with R.I. General Law §27-20-36. The testing must be performed in a facility that is: • accredited by the American Association of Blood Banks or its successors; and • licensed under the Clinical Laboratory Improvement Act as it may be amended from time to time. At the time of testing, the person being tested must complete and sign an informed consent form that also authorizes the results of the test to be used for participation in the National Marrow Donor program.

  • Mail Order Catalog Warnings In the event that, the Settling Entity prints new catalogs and sells units of the Products via mail order through such catalogs to California consumers or through its customers, the Settling Entity shall provide a warning for each unit of such Product both on the label in accordance with subsection 2.4 above, and in the catalog in a manner that clearly associates the warning with the specific Product being purchased. Any warning provided in a mail order catalog shall be in the same type size or larger than other consumer information conveyed for such Product within the catalog and shall be located on the same display page of the item. The catalog warning may use the Short-Form Warning content described in subsection 2.3(b) if the language provided on the Product label also uses the Short-Form Warning.

  • COVID-19 Vaccine Passports Pursuant to Texas Health and Safety Code, Section 161.0085(c), Contractor certifies that it does not require its customers to provide any documentation certifying the customer’s COVID-19 vaccination or post-transmission recovery on entry to, to gain access to, or to receive service from the Contractor’s business. Contractor acknowledges that such a vaccine or recovery requirement would make Contractor ineligible for a state-funded contract.

  • Speech Therapy This plan covers speech therapy services when provided by a qualified licensed • loss of speech or communication function; or • impairment as a result of an acute illness or injury, or an acute exacerbation of a chronic disease. Speech therapy services must relate to: • performing basic functional communication; or • assessing or treating swallowing dysfunction. See Autism Services when speech therapy services are rendered as part of the treatment of autism spectrum disorder. The amount you pay and any benefit limit will be the same whether the services are provided for habilitative or rehabilitative purposes.

  • Unbundled Channelization (Multiplexing) 5.7.1 To the extent NewPhone is purchasing DS1 or DS3 or STS-1 Dedicated Transport pursuant to this Agreement, Unbundled Channelization (UC) provides the optional multiplexing capability that will allow a DS1 (1.544 Mbps) or DS3 (44.736 Mbps) or STS-1 (51.84 Mbps) Network Elements to be multiplexed or channelized at a BellSouth central office. Channelization can be accomplished through the use of a multiplexer or a digital cross-connect system at the discretion of BellSouth. Once UC has been installed, NewPhone may request channel activation on a channelized facility and BellSouth shall connect the requested facilities via COCIs. The COCI must be compatible with the lower capacity facility and ordered with the lower capacity facility. This service is available as defined in NECA 4. 5.7.2 BellSouth shall make available the following channelization systems and interfaces: 5.7.2.1 DS1 Channelization System: channelizes a DS1 signal into a maximum of twenty- four (24)

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!